Zutectra
Human Hepatitis B Immunoglobulin 500 IU
Therapeutic Indication:
Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment starts.
The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.
- Composition: Human Hepatitis B Immunoglobulin 500 IU/ml
- Pharmaceutical Form: Solution for Infusion.
- Method of Administration: Intravenous.
- How Supplied: Pack of 5x 1ml Prefilled Syringes.
- Manufacturer: Biotest AG, Germany.